Figure 2From: Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study 24-h post-dose (trough) FEV 1 after 1 day and at Week 12 of treatment (ITT population). Data are LSM ± SEM. Significant treatment difference: ***p < 0.001 versus placebo. FEV1 = forced expiratory volume in 1 s; ITT = intent-to-treat; LSM = least squares means; SEM = standard error of mean.Back to article page